Ionis and Roche have struck a deal worth up to $760 million (£575 million) to develop a drug to treat advanced age-related macular degeneration (AMD), a leading cause of blindness.
It looks increasingly likely that Roche’s cancer blockbuster Rituxan (rituximab) will face competition from a cheaper biosimilar in the coming months after backing from an FDA expert commit
People with relapsing multiple sclerosis treated sooner with Roche’s Ocrevus saw a faster reduction in disease activity and less disability compared with those who switched from an older dr
Reviewers from the FDA have given Celltrion’s biosimilar of Roche’s blood cancer blockbuster Rituxan a glowing report ahead of a key meeting of its advisers tomorrow.
Roche’s Hemlibra has been approved in an expanded use in haemophilia A in the US, as the Swiss firm seeks to build a new blockbuster franchise in rare diseases.
Baloxavir marboxil, a flu drug seen by Roche as a successor to Tamiflu, significantly sped time to relief for patients highly vulnerable to serious complications.